Trial Profile
The Role of Inflammation in Brain and Cognitive Function in Mental Disorders
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Mar 2024
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Schizoaffective disorder; Schizophrenia
- Focus Therapeutic Use
- Acronyms IRIS
- 07 Mar 2024 Status changed from recruiting to completed.
- 23 Mar 2023 Planned End Date changed from 31 Mar 2023 to 30 Sep 2023.
- 23 Mar 2023 Planned primary completion date changed from 31 Mar 2023 to 30 Sep 2023.